izpis_h1_title_alt

Glucagon-like peptide-1 receptor agonists in the management of type 2 diabetes mellitus and obesity : the impact of pharmacological properties and genetic factors
ID Klen, Jasna (Avtor), ID Dolžan, Vita (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (1,07 MB)
MD5: 5839972C4AD480CC01A2207D455282D1
URLURL - Izvorni URL, za dostop obiščite https://www.mdpi.com/1422-0067/23/7/3451 Povezava se odpre v novem oknu

Izvleček
Glucagon-like peptide-1 (GLP-1) receptor agonists are a new class of antihyperglycemic drugs that enhance appropriate pancreatic β-cell secretion, pancreatic α-cell (glucagon) suppression, decrease liver glucose production, increase satiety through their action on the central nervous system, slow gastric emptying time, and increase insulin action on peripheral tissue. They are effective in the management of type 2 diabetes mellitus and have a favorable effect on weight loss. Their cardiovascular and renal safety has been extensively investigated and confirmed in many clinical trials. Recently, evidence has shown that in addition to the existing approaches for the treatment of obesity, semaglutide in higher doses promotes weight loss and can be used as a drug to treat obesity. However, some T2DM and obese patients do not achieve a desired therapeutic effect of GLP-1 receptor agonists. This could be due to the multifactorial etiologies of T2DM and obesity, but genetic variability in the GLP-1 receptor or signaling pathways also needs to be considered in non-responders to GLP-1 receptor agonists. This review focuses on the pharmacological, clinical, and genetic factors that may influence the response to GLP-1 receptor agonists in the treatment of type 2 diabetes mellitus and obesity.

Jezik:Angleški jezik
Ključne besede:type 2 diabetes mellitus, obesity, GLP‐1 receptor agonists, incretins, cardiovascular safety, genetic polymorphisms
Vrsta gradiva:Članek v reviji
Tipologija:1.02 - Pregledni znanstveni članek
Organizacija:MF - Medicinska fakulteta
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2022
Št. strani:18 str.
Številčenje:Vol. 23, iss. 7, art. 3451
PID:20.500.12556/RUL-137512 Povezava se odpre v novem oknu
UDK:616.379
ISSN pri članku:1422-0067
DOI:10.3390/ijms23073451 Povezava se odpre v novem oknu
COBISS.SI-ID:101977091 Povezava se odpre v novem oknu
Datum objave v RUL:20.06.2022
Število ogledov:652
Število prenosov:166
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:International journal of molecular sciences
Skrajšan naslov:Int. j. mol. sci.
Založnik:MDPI
ISSN:1422-0067
COBISS.SI-ID:2779162 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:01.04.2022

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:diabetes mellitus tipa 2, debelost, agonisti receptorjev GLP-1

Projekti

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:P1-0170
Naslov:Molekulski mehanizmi uravnavanja celičnih procesov v povezavi z nekaterimi boleznimi pri človeku

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:P3-0298
Naslov:Geni, hormonske in osebnostne spremembe pri metabolnih motnjah

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj